Biosimilars

Biosimilars Fan Club Includes Free-Market Conservatives

July 06, 2020

Pacific Research Institute’s Winegarden Sees Dose of Competition as Way to Lower OOP Costs

Survey: Rheumatologists Still Reluctant to Switch Patients to Biosimilars

July 02, 2020

Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars. 

Challenges of Developing the Next Generation of Biosimilars

June 04, 2020

Proving therapeutic equivalence is a major hurdle.

Understanding Biosimilar Development and Approvals

June 04, 2020

Developing a biosimilar can be more challenging than developing the innovator product because of the need to match the attributes of a highly complex molecules.

11 Trends Influencing Biosimilars in 2020

May 18, 2020

The purpose of biosimilar is simple: reduce healthcare costs, pure and simple. Here are 11 trends affecting biosimilars over the last year in the U.S.

Health Execs: Here are 5 Important Takeaways About the Current Situation With Biosimilars

May 18, 2020

Just as we’ve seen the entire healthcare landscape change in 2020 because of  COVID-19, the world of biosimilars is ever-changing. 

Biosimilars in the Pipeline

January 02, 2020

Several biosimilars will come to market within the next few years.

Biosimilar Availability May Impact Drug Pricing

January 02, 2020

Study finds that biologics that faced competition from biosimilars showed reductions in net prices and leveling off of list price increases.

3 Ways Insurers Can Help Promote Biosimilar Adoption

May 01, 2019

The FDA Commissioner says that insurers can help biosimilar adoption by taking short-term financial losses over long-term drug savings. What else should they be doing?

x